Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 21;6(7):e70061.
doi: 10.1002/bco2.70061. eCollection 2025 Jul.

A pilot study evaluating the safety and efficacy of En-bloc holmium laser enucleation of the prostate in patients with a history of radiation therapy or high intensity focused ultrasound for management of organ confined prostate cancer with review of the literature

Renil S Titus  1 , Ansh Bhatia  2 , Joao G Porto  3 , Jean C Daher  3 , Adele Raymo  3 , Maggie Meyreles  3 , Archan Khandekar  3 , Aravindh Rathinam  3 , Jonathan Katz  3 , Robert Marcovich  3 , Hemendra N Shah  3
Affiliations

A pilot study evaluating the safety and efficacy of En-bloc holmium laser enucleation of the prostate in patients with a history of radiation therapy or high intensity focused ultrasound for management of organ confined prostate cancer with review of the literature

Renil S Titus et al. BJUI Compass. .

Abstract

Objectives: To evaluate the safety and efficacy of Holmium Laser Enucleation of the Prostate (HoLEP) in managing patients with a history of organ-preserving treatments (OPT: Radiation Therapy - RT, High Intensity Focused Ultrasound - HIFU) for Organ-Confined Prostate Cancer (OC-PCa).

Methods: We reviewed men undergoing "en-bloc" HoLEP between July 2017 and December 2023 from our institutional database to identify those with a history of OPT for OC-PCa (study group). A 1:2 matched-pair analysis was performed comparing these patients with a control group of men undergoing HoLEP for benign prostatic hyperplasia (BPH) without prior OPT. Demographic, perioperative and postoperative voiding parameters up to 1 year, as well as complications, were compared between groups. Unpaired t-tests were used for parametric variables and Wilcoxon Rank tests for non-parametric variables. A p-value<0.05 was considered statistically significant.

Results: Of 660 patients, 15 had prior OPT before HoLEP. The time between OPT and HoLEP ranged from 3-month to 12-year. Associated urethral stricture and/or extensive prostatic calcification were present in five patients. Demographic and preoperative parameters were similar between the groups. However, the study group patient had significantly less resected tissue and higher rate of urinary incontinence at 3-month. Two patients (13.3%) continued to experience incontinence at 1-year. There was no clinically significant difference in postoperative improvement in voiding parameters amongst both groups.

Conclusions: HoLEP in patients with history of OPT for treatment of OC-PCa is associated with a higher risk of transient urinary incontinence.

Keywords: BPH; HIFU; HoLEP; bladder outlet obstruction; complications; prostate cancer; radiation therapy.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest.

Similar articles

See all similar articles

References

    1. Cancer Today. Accessed December 6, 2024, https://gco.iarc.who.int/today/
    1. Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020;77(1):38–52. 10.1016/j.eururo.2019.08.005 - DOI - PubMed
    1. Al Hussein Al Awamlh B, Wallis CJD, Penson DF, Huang LC, Zhao Z, Conwill R, et al. Functional outcomes after localized prostate cancer treatment. Jama. 2024;331(4):302–317. 10.1001/jama.2023.26491 - DOI - PMC - PubMed
    1. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate‐cancer survivors. N Engl J Med. 2008;358(12):1250–1261. 10.1056/NEJMoa074311 - DOI - PubMed
    1. Flegar L, Thoduka SG, Mahnken AH, Figiel J, Heers H, Aksoy C, et al. Focal therapy for renal cancer: comparative trends in the USA and Germany from 2006 to 2020 and analysis of the German health care landscape. Urol Int. 2023;107(4):396–405. 10.1159/000528559 - DOI - PMC - PubMed

LinkOut - more resources